Haloperidol for Back Pain
Trial Summary
What is the purpose of this trial?
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of back pain. A total of 150 patients age 18-65 presenting to the emergency department with chief complaint of backpain will be enrolled from April 2024 - April 2025. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the drug Haloperidol for back pain?
Research suggests that Haloperidol can reduce the need for strong painkillers in various pain conditions and enhance the pain-relieving effects of opioids like morphine. It has been effective in reducing pain in conditions like severe radiation fibrosis and abdominal pain, indicating its potential to help with back pain as well.12345
How is the drug Haloperidol unique for treating back pain?
Haloperidol is unique for treating back pain because it is traditionally used as an antipsychotic medication to manage mental health conditions like schizophrenia, rather than pain management. This makes its use for back pain novel compared to other treatments that are specifically designed for pain relief.678910
Research Team
Jessica McCoy, MD
Principal Investigator
Western Michigan University Homer Stryker M.D. School of Medicine
Eligibility Criteria
This trial is for adults aged 18-65 who come to the Bronson ED with acute, non-traumatic back pain and a pain score over 5 cm. It's not suitable for those outside this age range or with different types of back pain.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Haloperidol or Ketoralac and symptom levels are recorded at 30, 60, and 90 minutes
Follow-up
Participants are monitored for safety and effectiveness after treatment via telephone
Treatment Details
Interventions
- Haloperidol
Haloperidol is already approved in United States, European Union, Canada, Japan for the following indications:
- Schizophrenia
- Acute psychosis
- Agitation
- Delirium
- Schizophrenia
- Acute psychosis
- Agitation
- Delirium
- Tourette's syndrome
- Schizophrenia
- Acute psychosis
- Agitation
- Delirium
- Schizophrenia
- Acute psychosis
- Agitation
- Delirium
Find a Clinic Near You
Who Is Running the Clinical Trial?
Western Michigan University School of Medicine
Lead Sponsor
Bronson Methodist Hospital
Collaborator